278 related articles for article (PubMed ID: 16614006)
1. Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
Pirson L; Baron F; Meuris N; Giet O; Castermans E; Greimers R; Di Stefano I; Gothot A; Beguin Y
Stem Cells; 2006 Jul; 24(7):1814-21. PubMed ID: 16614006
[TBL] [Abstract][Full Text] [Related]
2. Imatinib and nilotinib inhibit hematopoietic progenitor cell growth, but do not prevent adhesion, migration and engraftment of human cord blood CD34+ cells.
Belle L; Bruck F; Foguenne J; Gothot A; Beguin Y; Baron F; Briquet A
PLoS One; 2012; 7(12):e52564. PubMed ID: 23285088
[TBL] [Abstract][Full Text] [Related]
3. The alpha4beta1 and alpha5beta1 integrins mediate engraftment of granulocyte-colony-stimulating factor-mobilized human hematopoietic progenitor cells.
Carstanjen D; Gross A; Kosova N; Fichtner I; Salama A
Transfusion; 2005 Jul; 45(7):1192-200. PubMed ID: 15987366
[TBL] [Abstract][Full Text] [Related]
4. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
[TBL] [Abstract][Full Text] [Related]
5. Effects of imatinib on bone marrow engraftment in syngeneic mice.
Hoepfl J; Miething C; Grundler R; Götze KS; Peschel C; Duyster J
Leukemia; 2002 Sep; 16(9):1584-8. PubMed ID: 12200667
[TBL] [Abstract][Full Text] [Related]
6. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Kuroda J; Kimura S; Segawa H; Kobayashi Y; Yoshikawa T; Urasaki Y; Ueda T; Enjo F; Tokuda H; Ottmann OG; Maekawa T
Blood; 2003 Sep; 102(6):2229-35. PubMed ID: 12763930
[TBL] [Abstract][Full Text] [Related]
7. The late dividing population of gamma-retroviral vector transduced human mobilized peripheral blood progenitor cells contributes most to gene-marked cell engraftment in nonobese diabetic/severe combined immunodeficient mice.
Brenner S; Ryser MF; Whiting-Theobald NL; Gentsch M; Linton GF; Malech HL
Stem Cells; 2007 Jul; 25(7):1807-13. PubMed ID: 17464090
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
9. High CD133 expression levels in gastrointestinal stromal tumors.
Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
[TBL] [Abstract][Full Text] [Related]
10. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of imatinib on normal progenitor cells in vitro.
Bartolovic K; Balabanov S; Hartmann U; Komor M; Boehmler AM; Bühring HJ; Möhle R; Hoelzer D; Kanz L; Hofmann WK; Brümmendorf TH
Blood; 2004 Jan; 103(2):523-9. PubMed ID: 12969987
[TBL] [Abstract][Full Text] [Related]
12. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.
Vianello F; Villanova F; Tisato V; Lymperi S; Ho KK; Gomes AR; Marin D; Bonnet D; Apperley J; Lam EW; Dazzi F
Haematologica; 2010 Jul; 95(7):1081-9. PubMed ID: 20179085
[TBL] [Abstract][Full Text] [Related]
14. Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells.
Zhang C; Zhou C; Wu XJ; Yang M; Yang ZH; Xiong HZ; Zhou CP; Lu YX; Li Y; Li XN
Carcinogenesis; 2014 Dec; 35(12):2771-7. PubMed ID: 25269803
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo culture of human cord blood hematopoietic stem/progenitor cells adversely influences their distribution to other bone marrow compartments after intra-bone marrow transplantation.
Yamamura K; Ohishi K; Masuya M; Miyata E; Sugimoto Y; Nakamura S; Fujieda A; Araki H; Katayama N
Stem Cells; 2008 Feb; 26(2):543-9. PubMed ID: 17975223
[TBL] [Abstract][Full Text] [Related]
18. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
19. Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
Shinagawa K; Kitadai Y; Tanaka M; Sumida T; Onoyama M; Ohnishi M; Ohara E; Higashi Y; Tanaka S; Yasui W; Chayama K
Int J Cancer; 2013 Feb; 132(4):813-23. PubMed ID: 22821812
[TBL] [Abstract][Full Text] [Related]
20. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]